GC Cell Presents GCC2005 Phase 1a Progress
Predicted impact: Low
Phase 1a progress update repeats trial news already covered; restructuring risk was reported earlier.
GC Cell지씨셀
144510 · KOSDAQ · ₩144510 · 지씨셀
₩10,100▲ ₩350 (3.59%)End-of-day · Oct 30, 2026 · End-of-day prices.
GC Cell shares plunge as US partner halts NK therapy development… Ativa to undergo restructuring
Predicted impact: Medium
Same NK drug halt and restructuring already reported; GC Cell drop was 9%.
Ativa halts NK drug development, GC Cell plunges; business restructuring under review
Predicted impact: Medium
Partner halts NK drug development; GC Cell fell sharply, restructuring under review.
지씨셀, CD5 표적 CAR-NK 치료제 임상 1a상 중간결과 공개
Predicted impact: Low
Interim clinical trial results; a prior affiliate trial halt is already known.
GC Cell falls 9% after affiliate halts clinical trial [Why Bio]
Predicted impact: Medium
Affiliate clinical trial halt caused a 9% share drop; a notable but indirect setback.
튀르키예 보건부 장관 지씨셀 방문...세포치료제 현지 진출 논의
Predicted impact: Low
Turkish health minister visit to discuss cell therapy expansion; no size or deal disclosed.
지씨셀 아티바, 'AB-101' 임상 3상 진입 가시화
Predicted impact: Low· Actual: +4.5% vs sector, volume 0.4× normal (5 trading days)
Clinical phase 3 entry for AB-101 is a routine development milestone with no size given.
Also known as: GC Cell / 지씨셀 / 144510 / KRX:144510
Source: KRX statistical information